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Novelty statement:  
 This study demonstrates that metformin ± insulin treatment is linked to the lower 
incidence of pre-eclampsia than insulin treatment alone in women with gestational 
diabetes mellitus (GDM) or Type 2 DM; this is likely associated with reduced weight 
gain during pregnancy in those taking metformin.  
 In other high-risk pregnancies where hypoglycaemic agents are not essential, metformin 
does not appear beneficial.  
 The current clinical guidelines, which recommend insulin treatment as a first line choice 
in pregnancies complicated by diabetes should be reviewed in light of these findings 
and adequately designed RCTs with pre-eclampsia as a primary outcome carried are 
needed. 
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Abstract 
AIMS 
Hypertensive disorders in pregnancy, particularly pre-eclampsia, are the leading cause of 
maternal or foetal morbidity and mortality, and effective treatments are lacking. The aim of this 
study was to perform meta-analyses of studies evaluating the risk of pre-eclampsia in high-risk 
insulin-resistant women taking metformin prior to, or during, pregnancy. 
METHODS 
Medline, EMBASE, Web of Science and Scopus databases were searched. Both randomised 
controlled trials (RCTs) and prospective observational cohort studies (CSs) of metformin 
treatment vs. placebo/control or insulin, either prior to, or during, pregnancy were selected. The 
main outcome measure was the incidence of pre-eclampsia in each treatment group.  
RESULTS 
Overall, in five RCTs comparing metformin treatment (n=611) to placebo/control (n=609), no 
difference in the risk of pre-eclampsia was demonstrated (combined/pooled RR=0.86; 95% CI 
0.33-2.26; p=0.76; I2=66%). Meta-analysis of four CSs again showed no significant effect 
(RR=1.21; 95% CI 0.56-2.61; p=0.62; I2=30%). However, a meta-analysis of eight RCTs 
comparing metformin (n=838) to insulin (n=836) showed reduced risk of pre-eclampsia with 
metformin (RR=0.68; 95% CI 0.48-0.95; p=0.02; I2=0%). No heterogeneity was present in the 
metformin vs. insulin analysis of RCTs, whereas high levels of heterogeneity were present in 
studies comparing metformin to placebo/control. Pre-eclampsia was a secondary outcome in 
most of the studies. Mean weight gain from enrolment to delivery was lower in the metformin 
group (p=0.05, metformin vs. placebo; p=0.004, metformin vs. insulin). 
CONCLUSIONS  
In studies randomising pregnant women to glucose-lowering therapy, metformin is associated 
with smaller gestational weight gain and a lower risk of pre-eclampsia than insulin.   
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Introduction  
Pre-eclampsia is a complication of pregnancy that occurs in the second half of gestation. It is 
defined as the new onset, after 20 weeks gestation, of hypertension (≥140/90 mmHg) and 
proteinuria (≥300 mg per 24 h), or in the absence of proteinuria, any of the following: 
thrombocytopenia (platelets<100,000/μl), impaired liver function, progressive renal 
insufficiency, pulmonary oedema or cerebral or visual disturbances[1]. Pre-eclampsia is 
classified according to gestational age at onset: term pre-eclampsia (onset ≥37 weeks), preterm 
pre-eclampsia (34-37 weeks), and early-onset pre-eclampsia (<34 weeks)[2]. Severe features 
of pre-eclampsia include blood pressure ≥160/110 mmHg, thrombocytopenia, impaired liver 
function, progressive renal insufficiency, pulmonary oedema, cerebral or visual 
disturbances[1]. Pre-eclampsia is the leading cause of maternal and foetal morbidity and 
mortality: by conservative estimates, it affects 10 million pregnant women worldwide annually, 
and is responsible for 76,000 maternal and 500,000 infant deaths[3]. In addition to the short-
term risks, pre-eclampsia is associated, later in life, with cardiovascular disease and/or Type 2 
diabetes mellitus (Type 2 DM) in both mothers and offspring[4,5].  
The incidence of pre-eclampsia is ~4-6% in the general population, but is greatly increased by 
insulin-resistant disorders such as gestational diabetes (GDM), Type 2 DM, polycystic ovary 
syndrome (PCOS) and obesity[6–8]. In women with pre-gestational diabetes, whether Type 1 
or Type 2 DM, the risk for pre-eclampsia in increased approximately four-fold[9,10].  
There are currently no reliable biomarkers or effective preventative measures, and no 
treatments for pre-eclampsia other than delivery. The pathogenesis of pre-eclampsia is linked 
to aberrant angiogenesis and inadequate remodelling of the spiral uterine artery, later leading 
to the development of an ischemic placenta; however, understanding of underlying mechanisms 
is inadequate, impeding the rational for development of preventative and treatment strategies.  
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A few therapeutic approaches have been explored. Low dose aspirin (75 mg daily) may reduce 
the incidence of pre-eclampsia by up to 25% if taken before 16 weeks gestation[11], and is 
recommended from 12 weeks gestation for women who have one or more of the following risk 
factors: history of pre-eclampsia, multifoetal gestation, chronic hypertension, diabetes (Type 1 
or 2 DM), renal disease or autoimmune disease (e.g. systemic lupus erythematous, 
antiphospholipid syndrome). Anti-oxidant supplements have also been assessed, but so far 
failed to show benefit in the prevention of pre-eclampsia[10].   
Metformin can be safely used in pregnancy[12] enabling investigation of its effects on 
pregnancy outcomes in women who are at higher risk such as obese women or women with 
GDM, Type 2 DM, or PCOS[13–16]. Metformin reduces insulin resistance, and mitigates 
endothelial dysfunction and hyperglycaemia, factors which have been associated with pre-
eclampsia[17,18]. Metformin is an AMPK activator, and reduced AMPK pathway activity has 
also been implicated in the pathogenesis of pre-eclampsia[19,20]. It is established that the 
circulating anti-angiogenic factor, fms-like tyrosine kinase 1 (sFlt-1) is significantly increased 
in pregnancies complicated by pre-eclampsia, and recently, it was demonstrated that metformin 
can reduce sFlt-1 secretion from placental tissue and placental explants[21]. Metformin 
therefore warrants investigation as a preventive treatment for pre-eclampsia.  
The aim of this systematic review and meta-analysis is to evaluate evidence concerning the 
efficacy of metformin compared to placebo/control or insulin in reducing the incidence of pre-
eclampsia in high-risk pregnant women using randomised controlled trials (RCTs) and 
prospective observational studies. 
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Methods 
Data sources and searches  
A systematic literature search was conducted using Medline (1946), Embase (1974), Web of 
Science, and Scopus databases for eligible studies from inception until November 2016. Filters 
were not used for the type of study or language, however only studies in human populations 
were included.  In collaboration with the subject librarian (RF) at the Medical Library, Queen’s 
University Belfast, the following terms and keywords were used: a) “Metformin or 
Glucophage”, b) “Pre-eclampsia or Pre-eclamp* or Preeclampsia or Preeclamp*” and c) 
“Gestational hypertension or Pregnancy-induced hypertension”. Combinations of a) AND b) 
or a) AND c) were also used.  
 
Study inclusion criteria 
Only those studies that met all of the following criteria were considered: 1) original study; 2) 
RCT or prospective observational study/cohort study (CS); 3) women took metformin before 
pregnancy and/or during pregnancy, and 4) women were followed throughout the pregnancy 
and pregnancy outcomes were recorded. We only included studies in which pre-eclampsia was 
diagnosed based on the following criteria as per guidelines by the American College of 
Obstetricians and Gynaecologists guidelines [1]: at least two consecutive blood pressure 
measures ≥140/90 mm Hg with proteinuria (≥0.3 g per 24 hours or 2+ on dipstick testing), with 
documented onset after gestational week 20. Three studies were included that defined and 
diagnosed pre-eclampsia in women with new onset hypertension in the absence of proteinuria 
but with one of the following: haematological involvement, liver involvement, neurological 
involvement, pulmonary oedema, foetal growth restriction or placental abruption[13,14,22].  
 
Data Extraction 
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The following data were extracted from the 18 studies selected: study characteristics (author, 
year of publication, country), population characteristics (age, body mass index (BMI) at 
enrolment, blood pressure at baseline, weight change during pregnancy, glycaemic control), 
treatment design (number of women on metformin or placebo/insulin, dose of metformin and 
duration of treatment) and outcomes (primary and secondary outcomes), Table 1.   
 
Quality Assessment 
Quality assessment of the included studies was independently performed by two reviewers (AA 
and LM) using Critical Appraisal Skills Programme [CASP, c/o Better Value Healthcare Ltd, 
Oxford] tools specifically designed for RCTs and CSs. Assessment was based on the eleven 
criteria, with one point being awarded for each if met in the study. The eleven criteria were: 1) 
clearly focused issue addressed (RCTs and CSs), 2) appropriate randomisation (RCTs) or 
appropriateness of the method used (CSs), 3) appropriate blinding (RCTs) or recruitment (CSs), 
4) matching baseline characteristics (RCTs) or controls selected in an acceptable way (CSs), 5) 
equal treatment of the groups (RCTs) or biased minimised (CSs), 6) follow-up of the women 
(RCTs) or adjusted for confounding factors (CSs), 7) the significance of the results (RCTs and 
CSs), 8) the size effect and precision of the results (RCTs and CSs), 9) ability to apply results 
locally (RCTs) or how believable the results are (CSs), 10) primary and secondary outcomes 
(RCTs) or ability to apply results locally (CSs), and 11) whether benefit is worth the harm and 
costs (RCTs) or whether the results fit other available evidence (CSs). The scores were 
compared between the two reviewers (AA and LM) and any differences were discussed to reach 
a consensus.  
Assessing the risk of bias was only possible for RCTs. We used RevMan 5.3 (Cochrane, UK) 
software which automatically generated a panel representing overall risk of bias for each study 
based on A) random sequence generation, B) allocation and concealment, C) blinding of 
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participants and personnel, D) blinding outcome assessment, E) incomplete outcome data, F) 
selective reporting and G) other bias.   
 
Data synthesis and analysis 
Risk ratio (RR) and accompanying standard errors were extracted from each study in relation 
to pre-eclampsia. In each, unadjusted estimates were recorded. A meta-analysis was performed 
to obtain pooled RR for pre-eclampsia in pregnant women treated with metformin compared 
with placebo or insulin using RCTs only; for CSs metformin treatment was compared to control 
(diet control or healthy pregnancies) or insulin. Therefore, four separate analyses were 
performed to compare effects of metformin vs. placebo/control and metformin vs. insulin, in 
RCTs only or CSs only, on the incidence of pre-eclampsia. In our analyses, women taking 
metformin who subsequently needed insulin to maintain good glycaemic control during the 
course of the pregnancy were included in the metformin arm. Clinical outcomes in RCTs which 
have shown a positive association with pre-eclampsia (e.g. mean fasting blood glucose (FBG) 
from enrolment to delivery; HbA1c at 36-37 weeks; GDM incidence; mean weight gain from 
enrolment to delivery), where available, were used to perform a meta-analysis to obtain pooled 
standard mean differences in pregnant women treated with metformin compared with placebo 
or insulin. A meta-analysis was also performed to examine if pooled standard mean differences 
in age and BMI were different in pregnant women treated with metformin compared with 
control in CSs.  
Random effects models were used to combine estimates to account for any heterogeneity 
present in the studies. Heterogeneity among studies was tested using a Chi-squared test and 
measured using the I-squared statistic. RevMan 5.3 software (The Nordic Cochrane Centre, 
The Cochrane Collaboration, Copenhagen, Denmark) and Stata 12 software (StataCorp LP, 
College Station, TX) were used to carry out these analyses. First, both RCTs and CSs were 
8 
 
included in the meta-analyses. Following this, only RCTs were included in the meta-analyses. 
Publication bias was assessed by funnel plots representing the log RR against the standard 
error[23].  
 
Results 
Study selection 
As depicted in the PRISMA flow chart (Fig. 1), the database search and literature screening 
yielded 364 studies. After removing duplicates, two reviewers (AA and LM) screened titles and 
abstracts of remaining 321 articles. Following initial screening 293 articles were excluded 
because they did not meet the inclusion criteria and were outside of the scope of the review. 
Two reviewers (AA and LM) independently assessed full text of remaining 28 articles. Three 
were excluded because they repeated findings from another included study. Three studies did 
not clearly define pre-eclampsia. Three studies were excluded because corresponding authors 
did not respond to requests for clarification or additional information[24–26]. This yielded a 
total number of 19 studies. The selected studies compared metformin treatment to a healthy 
cohort of women or a healthy diet (n=5)[22,27–30], or placebo (n=4)[14,16,31,32], or insulin 
(n=11)[13,15,22,33–40] (one study, with three treatment arms, was included both in metformin 
vs. control and metformin vs. insulin analysis[22]). The groups of women recruited into 
selected studies included women with GDM (n=7)[13,15,22,35–37], Type 2 DM (n=1)[34], 
women with both GDM and Type 2 DM (n=3)[37–39], PCOS (n=6)[16,27–30,32] and obese 
women (n=2)[14,31]. The quality scores based on the CASP tool assessment for each study are 
listed in the Supplementary table 1. The main categories where the CSs scored lower include: 
recruitment, acceptable controls , adjustment for confounding factors and application of the 
results to the local community. Some RCTs were scored lower in the categories such as 
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appropriate blinding (metformin vs. insulin RCTs), the size effect and precision of the results, 
ability to apply results locally (RCTs) and primary and secondary outcomes. 
 
Study characteristics  
Characteristics of the 19 selected studies are described in detail in Table 1. Fourteen RCTs[13–
16,30–38,40] and five CSs [22,27–29,39] studies were included. The baseline age range for all 
the women (n=3,374) was 16-46 years; most of the studies included women less than 35 years 
old. The majority of women were overweight (BMI: 25-30 kg/m², 35%) or obese (BMI>30 
kg/m², 64%); only 1% had a normal BMI at enrollment. Metformin treatment was initiated 
before pregnancy in three out of 19 studies[27-29], all in women with PCOS, in whom the aim 
was to enhance fertility. Pre-eclampsia was reported as a primary outcome only in four studies 
[16,27,29,39] and as a secondary outcome in sixteen studies [13–15,22,28,30–38,40]. All 
studies were published in or after the year 2000. The studies were carried out worldwide: 
Australia (n=1); Brazil (n=1); Denmark (n=1); Finland (n=2); Ghana (n=1); Italy (n=1), Iran 
(n=2); New Zealand (n=2); Norway (n=2); Pakistan (n=2); UK (n=2); USA (n=3).    
 
Meta-analysis of pre-eclampsia incidence 
A meta-analysis of five RCTs [14,16,30–32] comparing the effects of metformin vs. placebo 
included 1,220 pregnant women (611 in the metformin group, and 609 in the placebo group; 
Fig. 2a). There was no significant difference in the incidence of pre-eclampsia between these 
two groups; RR in the treatment arm was 0.86 (95% CI 0.33-2.26; p=0.76). There was a 
significant heterogeneity among these five studies (I²=66%, p=0.02). When the four 
prospective observational CSs [22,28,29,27] were combined in a meta-analysis, the RR was 
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1.21 (95% CI 0.56-2.61; p=0.62), also demonstrating no difference between metformin vs. 
control group (diet or no intervention) in terms of pre-eclampsia incidence. Heterogeneity was 
acceptable at 30%. However, three out of four CSs compared a group of women with PCOS 
taking metformin vs. a group of healthy pregnany women, which yielded similar pre-eclampsia 
incidence between the two groups, therefore suggesting possible benefit of metformin in PCOS 
cohort of pregnant women[27-29].  
When the effects of metformin vs. insulin were compared, following exclusion of one RCT[40] 
in which a high risk of bias was discovered (RevMan 5.3 risk of bias assessment), a meta-
analysis of eight RCTs [13,15,33–38] was performed. This meta-analysis included 1,674 
pregnant women (838 on metformin treatment and 836 on insulin treatment) and demonstrated 
a reduction in pre-eclampsia incidence associated with metformin (RR=0.68; 95% CI 0.48-
0.95, p=0.02; Fig. 2c). There was no heterogeneity among these studies in relation to pre-
eclampsia incidence (I²=0%). A meta-analysis of two CSs [22,39] included 956 pregnanies 
(515 in metformin group and 441 in insulin group) and found no difference in the incidence of 
pre-eclampsia (RR=1.61, 95% CI 0.42-6.12, p=0.49, Fig. 2d), however, the results are difficult 
to interpret due to the small number of studies included and significant heterogeneity between 
the studies of 79%. All meta-analyses performed, associated forest and funnel plots, and the 
risk of bias assessment for RCTs are summarized in Fig. 2.   
 
Meta-analyses of clinical characteristics associated with pre-eclampsia 
Advanced age, BMI, GDM, glycemic control in women with diabetes and weight gain during 
pregnancy have all been strongly and independently associated with pre-eclampsia[2,9,17,41–
43] and, for this reason, we evaluated if incidence of GDM or glycaemic control and weight 
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gain status differed between metformin and control or insulin groups, We also explored whether 
baseline BMI and age differed between groups in CSs.   
Metformin vs. control. As the randomisation process in RCTs ensures an even distribution of 
clinical characteristsics between intervention and control groups, the baseline differences in 
BMI and age in metfomin vs control groups was examined in CSs only. A meta-analyses of 
pooled BMI means from three CSs[27–29] showed a significant difference between metformin 
and control groups (p<0.001, Fig. 3a) and no heterogeneity amongst studies included. This was 
not surprising as all of these studies used a healthy pregnancy cohort as a control group, 
therefore suggesting that BMI is a confounding factor in this analysis. When the same analysis 
was carried out for age three CSs [27-29], no difference was demonstrated between the 
metformin vs. control group (p=0.28, Fig. 3b).    
With regard to the incidence of dysglycaemia in PCOS and obese women, no difference was 
found in the number of GDM cases between metformin and placebo group in RCTs (n=522 in 
metformin group and n=499 in placebo group; RR=0.89, 95% CI 0.69–1.16, p=0.4; Fig. 4a), or 
between metformin and control group in CSs (n=714 in metformin group and n=888 in control 
group; RR=0.80, 95% CI 0.39-1.64, p=0.54; Fig. 4b). Heterogeneity between the studies was 
zero with RCTs and 67% with CSs. 
Mean weight gain from enrolment to delivery was reported in three RCTs[14,16,31] comparing 
metformin to placebo and meta-analysis of this data indicated that weight gain was lower in the 
metformin versus control groups (p=0.05; Fig. 4c). However, heterogeneity amongst the studies 
was very high (I2=93%) therefore it is difficult to interpret this finding. 
Metformin vs. insulin. In relation to glycaemic control we investigated differences in mean FBG 
and HbA1c between metformin and insulin groups from enrollment until week 36-37. The 
mean FBG was recorded in six studies[13,15,34,36–38] whereas HbA1c was recorded in five 
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studies[13,15,33,36,37]. There were no significant differences between metformin and insulin 
treatment groups in relation to FBG (p=0.36; Fig. 5a) and HbA1c (p=0.73, mmol/mol, Fig. 5b; 
p=0.75, %, Supplementary Fig. S1). The percentage of women in the metfomin group who 
subsequently received insulin ranged from 14-85% (Supplementary Table S2). The two biggest 
studies reported that, between them, 33% of women in the metformin groups received 
supplementary insulin[13,33].  
There was substantial variation in the way that weight gain was recorded, so that mean weight 
gain could only be included from four out of seven studies which included metformin and 
insulin groups, in the meta-analysis[13,33,36,37]. These studies recorded weight gain from 
enrolment to delivery; in three studies women were enrolled from approx. 20-34 weeks 
gestation[13,33,36], whereas one study enrolled women from 10-22 weeks gestations[37]. A 
meta-analysis of pooled mean weight gain from entry to delivery demonstrated that women on 
metformin gained less weight during pregnancy than women on insulin (p=0.004; Fig. 5c).   
High heterogeneity was reported between the studies in relation to the following clinical 
parameters that were included in the meta-analyses: FBG (I2= 66%), HbA1c (I2=78%) and 
mean weight gain (I2=78%). 
 
Discussion  
This is the first systematic review and meta-analysis that focuses on the incidence of pre-
eclampsia in pregnant women taking metformin vs. placebo or insulin and elucidates potential 
clinical mechanisms in insulin-resistant women. Here, we analysed and critically appraised 
both prospective observational clinical studies and RCTs, which compared the use of 
metformin treatment with placebo/control or insulin treatment in pregnant women with insulin-
resistant disorders such as PCOS, obesity, Type 2 DM and GDM. Such women are at higher 
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risk of developing complications of pregnancy including pre-eclampsia. We performed meta-
analyses separately for CSs and RCTs. We also carried out two separate analyses comparing 
results for metformin vs. placebo/control and metformin vs. insulin.  
Metformin vs. placebo/control.  The results obtained suggest that there is no difference in the 
incidence of pre-eclampsia between women given metformin vs. placebo or control. We 
recognize that in the RCTs, the presence of a placebo arm implies that a hypoglycaemic agent 
was not clinically mandated (e.g. PCOS and obese cohorts), and therefore eligible participants 
are likely to have lesser risk factors than those requiring randomisation to metformin vs. insulin 
(Type 2 DM and GDM cohorts). Limitations of some studies included comparison of 
metformin-treated women with PCOS to healthy pregnant controls[27-29]. This was reflected 
in the meta-analysis of clinical characteristics which found BMI to be higher in metformin than 
the control group in the CS analysis, and hence is likely to be a confounding factor in relation 
to risk of pre-eclampsia. Another limitation was that pre-eclampsia was the primary outcome 
in only four of nine studies: three observational[27,29,39] and one RCT[16]. The heterogeneity 
between metformin vs. placebo RCTs was also high, therefore the results are difficult to 
interpret. 
Only two studies comparing metformin to placebo recruited obese women with BMI> 30 kg/m2 
and without diabetes, and, although of similar size, these two studies reached opposite 
conclusions[14,31]. In one, the number of women with pre-eclampsia was significantly lower 
in metformin group (odds ratio [OR] = 0.24; p=0.001)[14], whereas in the other, although 
statistical significance was not reached, a higher incidence of pre-eclampsia was reported in 
metformin group (OR=2.39; p=0.21)[31]. The baseline characteristics of the participants in 
both studies were very similar except that one study included all white women[31] whereas the 
other study included all racial groups and therefore was more representative of the general 
population in the UK [14]. In the latter study, lower incidence of pre-eclampsia was observed 
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in the metformin group compared to placebo.  In both, pre-eclampsia was recorded as a 
secondary outcome.   
Furthermore, the incidence of GDM was not different between metformin and placebo/control 
groups whether RCTs or CSs were examined suggesting that metformin did not have a 
significant effect on preventing GDM. Women who develop GDM have a higher incidence of 
pre-eclampsia[17], therefore it is possible that metformin in these cohorts of women was unable 
to prevent GDM (Fig. 4a,b), and, as a result, no difference in pre-eclampsia incidence was 
observed. On the other hand, weight gain, which was only reported in three RCTs[14,16,31], 
was borderline significant in favour of metformin being associated with lower weight gain 
during pregnancy. Therefore, the effect of metformin on weight gain, therefore, appears to be 
more pronounced in people with DM vs. without DM. 
Despite the fact that metformin activates the AMPK pathway, an effect which has been shown 
to inhibit processes directly relevant to the pathogenesis of pre-eclampsia such as irregular 
angiogenesis, endothelial dysfunction and inappropriate placental development[19–21], it did 
not demonstrate superiority over placebo/control in reducing the incidence of pre-eclampsia in 
this meta-analysis. Interestingly, Vanky and colleagues reported that severe pregnancy 
complications, which included pre-term delivery before 32 weeks, severe pre-eclampsia or 
serious post-partum events occurred only in the placebo group (placebo, 7/22 vs. metformin, 
0/18, p=0.01)[32]. The effect of metformin vs. placebo on severe pre-eclampsia should, 
therefore, be investigated in the future. 
Interestingly, clinical studies which assessed cardiovascular effects of metformin in people 
without Type 2 DM, showed little or no effect on the markers of cardiovascular disease[44]; 
the Diabetes Prevention Program also demonstrated no beneficial effect of metformin in 
reducing the incidence of hypertension in people without Type 2 DM[45]. Conversely, in 
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people with Type 2 DM the cardiovascular benefits of metformin were well substantiated in 
the UKPDS trial[46]. This differential effect of metformin in people with vs. without DM could 
also be relevant to pre-eclampsia, a disease of cardiovascular system, characterised by 
hypertension and proteinuria. 
Metformin vs. Insulin.  The comparison between metformin and insulin demonstrated a 
reduction in RR of pre-eclampsia in favour of metformin in the meta-analysis of RCTs. This 
result is convincing considering there was no heterogeneity between the studies. Nevertheless, 
in these studies, a common weakness was that neither the investigators nor the participants were 
blinded because of the different routes of administration of the study drugs. Glycaemic control 
was similar between groups at the start or throughout the trial; weight gain after enrolment was 
significantly lower in metformin group. Weight gain has been linked to an increased risk of 
pre-eclampsia[47]. Other possibilities for bias included a high risk for random sequence 
generation, and allocation concealment which was present in two studies[15,34].  
Considering all studies, on average 45% of the women in the metformin group needed 
supplementary insulin (Supplementary Table S2). When we carried out meta-analysis 
comparing metformin alone vs. insulin alone, which included six RCTs [Supplementary Fig. 
S2], the incidence of pre-eclampsia remained lower in the metformin group but significance 
was lost (p=0.18, RCTs and CSs; p=0.21; RCTs only). Administration of aspirin was not 
reported in any of the studies included. Nevertheless, most of these studies are relatively small, 
and therefore there may still be justification for a larger study with pre-eclampsia as a primary 
outcome, to address the question definitively.   
Overall, even though metformin ± insulin vs. insulin alone was associated with a lower risk for 
pre-eclampsia, it is unclear whether this is because insulin itself might increase the risk of pre-
eclampsia, perhaps in part by causing weight gain, or whether this is a beneficial effect of 
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metformin. A large population-based registry study in Finland[48] compared pregnancy 
outcomes in women with GDM who were below or over 35 years of age vs. women without 
GDM in the same age groups. Women with GDM were treated with diet or insulin. We 
calculated RR for pre-eclampsia, based on the data presented in the paper, between women 
with GDM treated on diet vs. insulin treatment in both age groups. This showed that in women 
with GDM who were below 35 years of age, insulin (238/2845) increased the risk of pre-
eclampsia (RR=1.19; CI 1.04 – 1.36; p=0.0092) compared to diet  (1161/19422); no difference 
was found in the prevalence of pre-eclampsia between diet and insulin group in women with 
GDM who were over 35 years of age. Most of the women (>90%) in our meta-analysis were 
younger than 35 years, which suggests that metformin may only have a marginal effect on 
preventing the risk of pre-eclampsia, however, it is still a better option than insulin alone in 
terms of the risk of pre-eclampsia and possibly other pregnancy complications. Further trials 
are needed to explore the incidence of pre-eclampsia between insulin and diet interventions. 
Perhaps prospective studies comparing insulin treatment to diet in women with GDM or Type 
2 DM could address this question. It is possible that metformin could have advantages over 
insulin in pregnant women who require a hypoglycaemic agent; these advantages could be even 
more pronounced in women over the age of 35 according to the findings by Lamminpää and 
colleagues[48]. Nevertheless, these women might still need insulin supplementation in the later 
stages of pregnancy to control hyperglycaemia. In women on metformin ± insulin, the weight 
gain is less than in women on insulin alone, and it is likely that the dose of insulin may be lower 
when metformin is used: both factors are potentially beneficial in relation to pre-eclampsia. In 
contrast, in the studies comparing metformin with placebo or no treatment, hypoglycaemic 
intervention was either optional or not needed: in these women, the data show no evidence in 
favour of metformin in reducing the risk of pre-eclampsia. It is important to explore further the 
effects of metformin vs. placebo/control on the early or severe type of pre-eclampsia 
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characterised by onset of pre-eclampsia before 34 weeks gestation or blood pressure ≥160/110 
mmHg. It is possible, as suggested by Myatt and colleagues, that there are different phenotypes 
of pre-eclampsia and that this is the reason why large clinical studies have failed to validate 
findings observed in the smaller studies[49]. Therefore, correct stratification of high-risk 
women according to age, presence of diabetes, blood pressure or BMI is important and this 
could determine the most appropriate preventative treatment. Also, women with GDM or Type 
2 DM during pregnancy are frequently given, or swapped to, insulin instead of metformin. 
These women are at high risk of pre-eclampsia; it is possible, based on this review, and other 
published data, that metformin ± supplementary insulin would be a better option during 
pregnancy in these women than insulin alone. 
Clearly, in this systematic review we could not include (and did not find) any studies of 
pregnancy in Type 1 DM women. These women also have a four-fold increased risk of 
developing pre-eclampsia, similar to women with Type 2 DM[9,10]. Considering that 
metformin in addition to insulin appears beneficial compared to insulin alone, future 
randomised double-blind placebo-controlled trials investigating the ability of metformin, in 
addition to insulin, in prevention of pre-eclampsia in pregnant women with Type 1 DM could 
be valuable. In the current analysis, with a pre-eclampsia rate of 20% in the insulin group and 
14% in the metformin group (estimated based upon a 30% reduction in metformin group 
observed in this meta-analysis), 650 women with pre-gestational Type 1 DM would need to be 
recruited in each group to have over 80% power to detect this difference as statistically 
significant. 
 
Conclusion 
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In pregnant women requiring hypoglycaemic treatment, metformin alone or metformin in 
combination with insulin is associated with less weight gain and a lower incidence of pre-
eclampsia than insulin alone. This suggests that metformin ± supplementary insulin treatment 
is linked to more favourable pregnancy outcomes such as reduced risk of pre-eclampsia than 
insulin alone. This effect is likely to be age-dependent and associated with reduced weight gain 
during pregnancy. In other high-risk pregnancies where glucose-lowering agents are not 
essential, we did not find a case for prescribing metformin. Considering that metformin can 
safely be used in pregnancy, adequately designed and powered RCTs which have pre-eclampsia 
as a primary outcome should be carried out in the future in GDM or Type 2 DM, and perhaps 
in Type 1 DM pregnancies.  
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Table 1. Study characteristics and outcomes measured. 
Figure 1. PRISMA Guidelines flow diagram.  
Figure 2. Meta-analysis comparing the risk ratio of pre-eclampsia in metformin vs. non-
metformin treatment group. [A] A meta-analysis of RCTs comparing metformin to placebo. 
[B] A meta-analysis of cohort studies (CSs) comparing metformin to control group. [C] A meta-
analysis of RCTs comparing metformin to insulin. [D] A meta-analysis of CSs comparing 
metfomin to insulin. Random effects models were used to combine estimates and analyses were 
carried out using RevMan 5.3 software; risk ratio was calculated; the overall effect was 
measured using Z-test with p values less than 0.05 being statistically significant. Heterogeneity 
was calculated using Chi2 test and measured by I2 statistic. 
 
Figure 3. Meta-analyses of BMI and age in metformin vs. placebo treatment group. [A] A 
meta-analysis of CSs comparing BMI between metformin and control group. [B] A meta-
analysis of CSs comparing age between metformin and control group. Random effects models 
were used to combine estimates and analyses were carried out using RevMan 5.3 software; 
standard mean difference was calculated; the overall effect was measured using Z-test with p 
values less than 0.05 being statistically significant. Heterogeneity was calculated using Chi2 
test and measured by I2 statistic. 
 
Figure 4. Meta-analyses of the incidence of GDM and weight gain in metformin vs. 
placebo treatment group. [A] A meta-analysis comparing the risk ratio of gestational diabetes 
(GDM) between metformin and placebo group, RCTs combined. [B] A meta-analysis 
comparing the risk ratio of GDM between metformin and control group, CSs only. [C] A meta-
analysis of weight gain between enrolment and delivery, RCTs combined. Random effects 
models were used to combine estimates and analyses were carried out using RevMan 5.3 
software; standard mean difference or risk ratio was calculated; the overall effect was measured 
using Z-test with p values less than 0.05 being statistically significant. Heterogeneity was 
calculated using Chi2 test and measured by I2 statistic. 
 
Figure 5. Meta-analyses of clinical risk factors for pre-eclampsia in metformin vs. insulin 
treatment group, RCTs only. [A] A meta-analysis of mean fasting blood glucose [FBG] from 
enrolment to delivery. [B] A meta-analysis of glycated haemoglobin [HbA1c, mmol/mol] 
recorded between 36 and 37 weeks. [C] A meta-analysis of weight gain between enrolment and 
delivery. Random effects models were used to combine estimates and analyses were carried 
out using RevMan 5.3 software; standard mean difference was calculated; the overall effect 
was measured using Z-test with p values less than 0.05 being statistically significant. 
Heterogeneity was calculated using Chi2 test and measured by I2 statistic.  
 
Supplementary Table 1. Supplementary Table 2: Study quality assessment using CASP tool. 
 
Supplementary Table 2. Percentage of women in metformin group who were supplemented 
with additional insulin 
 
Supplementary Fig. 1. Meta-analyses of HbA1c [%] in metformin vs. insulin treatment group, 
RCTs only. A meta-analysis of glycated haemoglobin [HbA1c] recorded between 36 and 37 
weeks. Random effects models were used to combine estimates and analyses were carried out 
using RevMan 5.3 software; standard mean difference was calculated; the overall effect was 
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measured using Z-test with p values less than 0.05 being statistically significant. Heterogeneity 
was calculated using Chi2 test and measured by I2 statistic. 
 
Supplementary Fig. 2. A meta-analysis comparing the risk ratio of pre-eclampsia in metformin 
only vs. insulin only treatment group, RCTs combined. Random effects models were used to 
combine estimates and analyses were carried out using RevMan 5.3 software; risk ratio was 
calculated; the overall effect was measured using Z-test with p values less than 0.05 being 
statistically significant. Heterogeneity was calculated using Chi2 test and measured by I2 
statistic. 
 
